3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Peritoneal Neoplasms
1
Colorectal Neoplasms
1
Interventions
tremelimumab
1
poly(I).poly(c12,U)
1
olaparib
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
genexol-PM
1
abagovomab
1
Topotecan
1
Paclitaxel
1
Oxaliplatin
1
MOC31PE immunotoxin
1
LY-2157299
1
Introns
1
Interferon alpha-2
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gefitinib
1
Drug Therapy
1
Doxorubicin
1
Cytoreduction Surgical Procedures
1
Cisplatin
1
Celecoxib
1
Capecitabine
1
Bevacizumab
1
AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase
1
Acids
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Peritoneal Neoplasms
×
MOC31PE immunotoxin
×
Clear all
NCT02219893
2017-05-30
ImmunoPeCa
Oslo University Hospital
Phase 1/2
Completed
15 enrolled